Bullet-Points for Plasma Protein Binding

Fast – easy – reliable are good points for describing the innovative TRANSIL® ADME assays for Plasma Protein Binding by NIMBUS Biotechnology. The assays are delivered as ready to go plates (96/384 well) and available for every (high-)throughput in drug discovery and development. The small assay volumes (80 µL) are the solutions for critical compound resources and the high biological relevance of the results supports the decision process at all stages of the discovery project.

Quantification of plasma protein binding (HSA) of compounds is an important early screening step during drug discovery and is of fundamental interest for estimation of safety margins. The clinical potential of drug compounds is greatly affected by their interactions with plasma proteins, such as human serum albumin (HSA) and α₁-acid glycoprotein (AGP).

Wolfgang Lerch, CEO of the company, stated “NIMBUS Biotechnology offers smart tools to measure the binding of compounds to plasma proteins fast, reliable and precisely in human and rat. Colaborations with the pharmaceutical industry, such as with Bayer HealthCare AG and Altana Pharma AG, drive us to overcome bottlenecks and so to improve the complex process of drug discovery and development. Come and see us in Seattle!”